EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Exclusion Criteria

• •Bilateral breast cancer or carcinoma in situ DCIS/LCIS；
• •Have received chemotherapy for advanced disease；
• •Transfer of any part；
• •If any tumor \>T4a (accompanied by skin invasion, mass adhesion fixation, inflammatory breast cancer)；
• •Patients with clinical or imaging suspicion of malignancy on the opposite breast but not confirmed, requiring biopsy；
• •Have received neoadjuvant therapy, including chemotherapy, radiotherapy and endocrine therapy；
• •Malignant neoplasms (other than basal cell carcinoma of the skin and carcinoma in situ of the cervix), including contralateral breast cancer, within the previous 5 years；
• •The patient has been enrolled in other clinical trials；
• •Patients with severe systemic disease and/or uncontrolled infection were unable to be enrolled in the study；
• •LVEF\<50% (cardiac ultrasound)；
• •Severe cardiovascular and cerebrovascular disease (e.g., unstable angina, chronic heart failure, uncontrolled hypertension \>150/90mmgh, myocardial infarction or cerebrovascular accident) within 6 months prior to randomization；
• •Known allergy to related drugs；
• •Women of childbearing age refuse contraception during treatment and within 8 weeks after completion of treatment；
• •Pregnant and lactating women；
• •Those who tested positive for pregnancy before taking the drug after joining the trial；
• •Mental illness, cognitive impairment, inability to understand the trial protocol and side effects, inability to complete the trial protocol and follow-up workers ；(systematic evaluation is required before trial enrollment)；
• •Persons without personal freedom and independent capacity for civil conduct。